Protective Effects of Carvedilol and Vitamin C against Azithromycin-Induced Cardiotoxicity in Rats via Decreasing ROS, IL1- β, and TNF- α Production and Inhibiting NF- B and Caspase-3 Expression

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  El Shitany, Nagla A ^a,b   El Desoky, Karema ^c  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Tanta University   (Egypt)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDES; CELL DEATH; CONTROLLED DRUG DELIVERY; ENZYMES; NITRIC OXIDE; PEPTIDES;

CARDIAC MUSCLE FIBERS; CARDIOVASCULAR EVENT; FOOD AND DRUG ADMINISTRATION; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE; REACTIVE OXYGEN SPECIES; SUPER OXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

RATS;

ASCORBIC ACID; AZITHROMYCIN; CARVEDILOL; CASPASE 3; CREATINE KINASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; MALONALDEHYDE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE; CARDIOTOXICITY; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; HEART PROTECTION; HEART RATE; HISTOPATHOLOGY; MALE; MUSCLE ATROPHY; NONHUMAN; PR INTERVAL; PROTEIN EXPRESSION; QRS INTERVAL; QT INTERVAL; QTC INTERVAL; RAT; RR INTERVAL; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ASCORBIC ACID; AZITHROMYCIN; CARBAZOLES; CARDIOTOXICITY; CASPASE 3; ELECTROCARDIOGRAPHY; INTERLEUKIN-1BETA; MALE; NF-KAPPA B; PROPANOLAMINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84971222040     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/1874762     Document Type: Article

References (62)

1. Food and Drug Administration, FDA Statement Regarding Azithromycin (Zithromax) and the Risk of CardiovascularDeath, Food and Drug Administration, Silver Spring, Md, USA, 2012, http://www. fda. gov/Drugs/ DrugSafety/ucm304372. htm.
2. P. A. Howard, "Azithromycin-induced proarrhythmia and cardiovascular death, " Annals of Pharmacotherapy, vol. 47, no. 11, pp. 1547-1551, 2013.
3. N. Matsunaga, Y. Oki, and A. A. Prigollini, "A case of QT-interval prolongation precipitated by azithromycin, " New Zealand Medical Journal, vol. 116, no. 1185, articleU666, 2003.
4. V. Russo, G. Puzio, and N. Siniscalchi, "Azithromycin-induced QT prolongation in elderly patient, " Acta Biomedica, vol. 77, no. 1, pp. 30-32, 2006.
5. B.-H. Huang, C.-H. Wu, C.-P. Hsia, and C. Y. Chen, "Azithromycin-induced torsade de pointes, " Pacing and Clinical Electrophysiology, vol. 30, no. 12, pp. 1579-1582, 2007.
6. A. Kezerashvili, H. Khattak, A. Barsky, R. Nazari, and J. D. Fisher, "Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors, " Journal of Interventional Cardiac Electrophysiology, vol. 18, no. 3, pp. 243-246, 2007.
7. J. C. Hancox, M. Hasnain, W. V. Vieweg, E. L. Crouse, and A. Baranchuk, "Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative reviewbased onthe study of case reports, "Therapeutic Advances in Infectious Disease, vol. 1, no. 5, pp. 155-165, 2013.
8. H. Ohara, Y. Nakamura, Y. Watanabe et al., "Azithromycin can prolong QT interval and suppress ventricular contraction, but will not induce torsade de pointes, " Cardiovascular Toxicology, vol. 15, no. 3, pp. 232-240, 2014.
9. B. Shin, H. Y. Park, and W. J. Koh, "Changes inQT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease, " The International Journal of Tuberculosis and Lung Disease, vol. 18, no. 11, pp. 1385-1385, 2014.
10. T. Yu and T. Niu, "Giant inverted T waves and substantial QT interval prolongation induced by azithromycin in an elderly woman with renal insufficiency, " Canadian Family Physician, vol. 60, no. 11, pp. 1012-1015, 2014.
11. Z. K. Lu, J. Yuan, M. Li et al., "Cardiac risks associated with antibiotics: Azithromycin and levofloxacin, " Expert Opinion on Drug Safety, vol. 14, no. 2, pp. 295-303, 2015.
12. P. Samarendra, S. Kumari, S. J. Evans, T. J. Sacchi, and V. Navarro, "QT prolongation associated with azithromycin/ amiodarone combination, " Pacing and Clinical Electrophysiology, vol. 24, no. 10, pp. 1572-1574, 2001.
13. S. Amer, S. Hassan, M. Shariffi, and L. Chueca, "QT interval prolongation associated with azithromycin/methadone combination, " West IndianMedical Journal, vol. 62, no. 8, pp. 864-865, 2013.
14. A. D. Mosholder, J. Mathew, J. J. Alexander, H. Smith, and S. Nambiar, "Cardiovascular risks with azithromycin and other antibacterial drugs, "The New England Journal of Medicine, vol. 368, no. 18, pp. 1665-1668, 2013.
15. G. Cocco and P. Jerie, "Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: An unexpected dangerous interaction, " Cardiovascular Toxicology, vol. 15, no. 1, pp. 104-106, 2015.
16. O. Atli, O. S. Ilgin, H. Altuntas, and D. Burukoglu, "Evaluation of azithromycin induced cardiotoxicity in rats, " International Journal of Clinical and Experimental Medicine, vol. 8, no. 3, pp. 3681-3690, 2015.
17. J. R. Bullinga, R. Alharethi, M. S. Schram, M. R. Bristow, and E. M. Gilbert, "Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure, " Journal of Cardiac Failure, vol. 11, no. 9, pp. 693-699, 2005.
18. R. E. Shaddy, M. M. Boucek, D. T. Hsu et al., "Carvedilol for children and adolescents with heart failure: A randomized controlled trial, " The Journal of the American Medical Association, vol. 298, no. 10, pp. 1171-1179, 2007.
19. M. B. Oflaz, S. Balli, A. E. Kibar, I. Ece, C. Akdeniz, and V. Tuzcu, "Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy, " Medical Science Monitor, vol. 19, no. 1, pp. 366-372, 2013.
20. K. Premkumar and C. L. Bowlus, "Ascorbic acid does not increase the oxidative stress induced by dietary iron in C3H mice, " Journal of Nutrition, vol. 134, no. 2, pp. 435-438, 2004.
21. S. Englard and S. Seifter, "Thebiochemical functions of ascorbic acid, " Annual Review of Nutrition, vol. 6, pp. 365-406, 1986.
22. B. Bednarz, T. Chamiec, and L. Ceremuzýnski, "Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction, " Kardiologia Polska, vol. 58, no. 5, pp. 375-379, 2003.
23. Y.-H. Kim, S.-M. Park, M. Kim et al., "Cardioprotective effects of rosuvastatin and carvedilol on delayed cardiotoxicity of doxorubicin in rats, " Toxicology Mechanisms and Methods, vol. 22, no. 6, pp. 488-495, 2012.
24. A. H. M. Viswanatha Swamy, U. Wangikar, B. C. Koti, A. H. M. Thippeswamy, P. M. Ronad, and D. V. Manjula, "Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats, " Indian Journal of Pharmacology, vol. 43, no. 5, pp. 507-511, 2011.
25. K. J. Field, W. J. White, and C. M. Lang, "Anaesthetic effects of chloral hydrate, pentobarbitone and urethane in adult male rats, " Laboratory Animals, vol. 27, no. 3, pp. 258-269, 1993.
26. A. Azhar and H. M. El-Bassossy, "Pentoxifylline alleviates cardiac ischemia and dysfunction following experimental angina in insulin resistance, " PLoS ONE, vol. 9, no. 5, Article IDe98281, 2014.
27. A. J. Pesce, "Lactate dehydrogenase, " in Methods in Clinical Chemistry, pp. 903-906, 1987.
28. B. Abbot, D. S. Young, and A. Burtis, "Creatine kinase, " in Clinical Chemistry, A. Kaplan, Ed., pp. 1112-1116, The C. V. Mosby, St. Louis, Mo, USA, 1984.
29. M. Uchiyama and M. Mihara, "Determination of malonaldehyde precursor in tissues by thiobarbituric acid test, " Analytical Biochemistry, vol. 86, no. 1, pp. 271-278, 1978.
30. G. L. Ellman, "Tissue sulfhydryl groups, " Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70-77, 1959.
31. M. M. Tarpey, D. A. Wink, and M. B. Grisham, "Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations, " American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 286, no. 3, pp. R431-R444, 2004.
32. D. E. Paglia and W. N. Valentine, "Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase, " The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158-169, 1967.
33. M. Nishikimi, N. Appaji Rao, and K. Yagi, "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen, " Biochemical and Biophysical Research Communications, vol. 46, no. 2, pp. 849-854, 1972.
34. H. Aebi, "Catalase in vitro, "Methods in Enzymology, vol. 105, pp. 121-126, 1984.
35. A. Mazzoleni, M. E. Curtin, R. Wolff, L. Reiner, and G. Somes, "On the relationship between heart weights, fibrosis, and QRS duration, " Journal of Electrocardiology, vol. 8, no. 3, pp. 233-236, 1975.
36. A. K. Kela, L. P. Reddy, and D. P. Thombre, "E. C. G. findings in normal rats and after administration of isoproterenol, " Indian Journal of Physiology and Pharmacology, vol. 24, no. 2, pp. 84-90, 1980.
37. G.-X. Yan and C. Antzelevitch, "Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome, " Circulation, vol. 98, no. 18, pp. 1928-1936, 1998.
38. T. Liu, B. S. Brown, Y. Wu, C. Antzelevitch, P. R. Kowey, and G.-X. Yan, "Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of druginduced proarrhythmias, " Heart Rhythm, vol. 3, no. 8, pp. 948-956, 2006.
39. N. Watanabe, Y. Kobayashi, K. Tanno et al., "Transmural dispersion of repolarization and ventricular tachyarrhythmias, " Journal of Electrocardiology, vol. 37, no. 3, pp. 191-200, 2004.
40. P. Gupta, C. Patel, H. Patel et al., "T (p-e) /QT ratio as an index of arrhythmogenesis, " Journal Electrocardiology, vol. 41, no. 6, pp. 567-574, 2008.
41. A. Bilginoglu, D. Aydn, S. özsoy, and M. D. Hatice Aygün, "Protective effect of melatonin on adriamycin-induced cardiotoxicity in rats, " Türk Kardiyoloji Dernegi Arşivi, vol. 42, no. 3, pp. 265-273, 2014.
42. J. Hochrein, F. Sun, K. S. Pieper et al., "Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I Substudy), " The American Journal of Cardiology, vol. 81, no. 9, pp. 1078-1084, 1998.
43. S. Yilmaz, A. Atessahin, E. Sahna, I. Karahan, and S. Ozer, "Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity, " Toxicology, vol. 218, no. 2-3, pp. 164-171, 2006.
44. N. A. El-Shitany, S. El-Haggar, and K. El-desoky, "Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats, " Food and Chemical Toxicology, vol. 46, no. 7, pp. 2422-2428, 2008.
45. F. Salvemini, A. Franzé, A. Iervolino, S. Filosa, S. Salzano, and M. V. Ursini, "Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression, "The Journal of Biological Chemistry, vol. 274, no. 5, pp. 2750-2757, 1999.
46. W. S. Shin, A. Szuba, and S. G. Rockson, "The role of chemokines in human cardiovascular pathology: enhanced biological insights, " Atherosclerosis, vol. 160, no. 1, pp. 91-102, 2002.
47. X. Cai, W. Lu, Y. Yang, J. Yang, J. Ye, and Z. Gu, "Digitoflavone inhibits IB kinase and enhances apoptosis induced by TNF through down regulation of expression of nuclear factor Bregulated gene products in human pancreatic cancer cells, " PLoS ONE, vol. 8, no. 10, Article ID77126, 2013.
48. T. Rassaf, L. W. Poll, P. Brouzos et al., "Positive effects of nitric oxide on left ventricular function in humans, " European Heart Journal, vol. 27, no. 14, pp. 1699-1705, 2006.
49. S. Ishiyama, M. Hiroe, T. Nishikawa et al., "Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats, " Circulation, vol. 95, no. 2, pp. 489-496, 1997.
50. P. Pacher, R. Schulz, L. Liaudet, and C. Szabó, "Nitrosative stress and pharmacological modulation of heart failure, " Trends in Pharmacological Sciences, vol. 26, no. 6, pp. 302-310, 2005.
51. B. A. Abdel-Wahaba and M. E. Metwally, "Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF , " Cardiovascular Toxicology, vol. 15, no. 4, pp. 355-365, 2015.
52. A. Yildirir, E. Sade, L. Tokgozoglu, and A. Oto, "The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure, " European Journal of Heart Failure, vol. 3, no. 6, pp. 717-721, 2001.
53. M. Kawamura, Y. Munetsugu, K. Tanno, and Y. Kobayashi, "Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy, " Journal of Cardiovascular Pharmacology, vol. 61, no. 1, pp. 77-82, 2013.
54. B. Akdeniz, S. Guneri, I. Z. Savas et al., "Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure, " InternationalHeart Journal, vol. 47, no. 4, pp. 565-573, 2006.
55. C. H. Yadav, M. Akhtar, and R. Khanam, "Isoproterenol toxicity induced ECG alterations in wistar rats: role of histamine H3 receptor agonist imetit, " International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 5, pp. 654-658, 2014.
56. B. S. Thippeswamy, S. P. Thakker, S. Tubachi et al., "Cardioprotective effect of Cucumis trigonus roxb on isoproterenolinduced myocardial infarction in rat, " American Journal of Pharmacology and Toxicology, vol. 4, no. 2, pp. 29-37, 2009.
57. J. S. Patel, S. K. Setty, M. Chakraborty, and J. V. Kamath, "Evaluation of cardioprotective activity of Medohar vati by isoproterenol inducedmyocardial damage in rats, " International Research Journal of Pharmacy, vol. 3, no. 8, pp. 214-217, 2012.
58. K. Kurosaki, U. Ikeda, Y. Maeda, and K. Shimada, "Carvedilol stimulates nitric oxide synthesis in rat cardiac myocytes, " Journal of Molecular and Cellular Cardiology, vol. 32, no. 2, pp. 333-339, 2000.
59. H. Takano, S. Manchikalapudi, X.-L. Tang et al., "Nitric oxide synthase is themediator of late preconditioning againstmyocardial infarction in conscious rabbits, " Circulation, vol. 98, no. 5, pp. 441-449, 1998.
60. A. D. Lenarda, G. Sabbadini, L. Salvatore et al., "Long-term effects of carvedilol in idipathic dilated cardioin myopathy with persistent left ventricular dysfunction despite chronic metoprolol, " Journal the College, vol. 33, no. 7, pp. 1926-1934, 1999.
61. M. M. Abdel-Daim, E. W. Ghazy, and M. Fayez, "Synergistic protective role of mirazid (Commiphora molmol) and ascorbic acid against tilmicosin-induced cardiotoxicity in mice, " Canadian Journal of Physiology and Pharmacology, vol. 93, no. 1, pp. 45-51, 2015.
62. T. Yavuz, I. Altuntas, N. Delibas et al., "Cardiotoxicity in rats induced by methidathion and ameliorating effect of vitamins E and C, " Human and Experimental Toxicology, vol. 23, no. 7, pp. 323-329, 2004.